The FDA approved Cimerli as a biosimilar to and interchangeable with Lucentis, according to a press release from Coherus BioSciences.
The approval confirms that Cimerli (ranibizumab-eqrn), an anti-VEGF therapy that helps patients with retinal diseases maintain or gain vision, meets all FDA safety, efficacy and quality standards. It is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularization.
Results from the COLUMBUS-AMD study provided evidence that Cimerli’s